Trevi Therapeutics, Inc. TRVI Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $19.41M+0.2% | $18.91M-44.5% | $56.87M+254% | $117.06M+803% | $19.37M+40.3% | ||
| $152.37M+81.6% | $169.35M+130% | $138.06M+179% | $86.83M+53.6% | $83.88M+42.2% | ||
| $2.22M+44.8% | $1.26M+34.5% | $1.38M+16.9% | $1.77M-2.1% | $1.53M-52.6% | ||
| $176.12M+66.7% | $191.66M+75.1% | $198.3M+194% | $207.23M+187% | $105.62M+37.6% | ||
| $265K-4.3% | $178K+13.4% | $213K+22.4% | $239K+20.7% | $277K+35.8% | ||
| $610K-29.5% | $677K-26.0% | $741K-23.8% | $804K-21.9% | $865K-20.2% | ||
| $2.61M+983% | $928K+282% | $103K-59.8% | $68K-75.1% | $241K-22.5% | ||
| $179.61M+67.8% | $193.44M+74.4% | $199.36M+189% | $208.34M+182% | $107M+36.2% | ||
| $2.22M+55.9% | $3.91M+14.6% | $2.71M+67.8% | $2.97M+96.8% | $1.42M-32.7% | ||
| $4.58M-11.4% | $5.53M-18.8% | $6.04M-16.3% | $5.98M+21.3% | $5.17M+81.9% | ||
| $318K+15.2% | $307K+20.9% | $296K+26.0% | $286K+32.4% | $276K+39.4% | ||
| $7.12M+3.6% | $9.75M-7.2% | $9.04M-0.9% | $9.24M+36.9% | $6.87M+30.1% | ||
| $364K-46.5% | $446K-40.3% | $527K-35.4% | $605K-31.6% | $681K-28.2% | ||
| $7.48M-0.9% | $10.2M-9.4% | $9.57M-3.7% | $9.85M+28.9% | $7.55M+21.2% | ||
| —— | —— | —— | —— | —— | ||
| $128K+28.0% | $128K+36.2% | $128K+70.7% | $122K+67.1% | $100K+44.9% | ||
| $515.19M+29.9% | $512.77M+32.7% | $511.12M+52.9% | $508.03M+54.6% | $396.67M+23.0% | ||
| -$343M-15.3% | -$329.8M-14.9% | -$321.49M-16.6% | -$309.69M-18.0% | -$297.39M-18.9% | ||
| -$190K-360% | $148K+143% | $30K-78.4% | $24K+129% | $73K+209% | ||
| $172.13M+73.1% | $183.24M+83.9% | $189.79M+222% | $198.49M+200% | $99.46M+37.5% | ||
| $179.61M+67.8% | $193.44M+74.4% | $199.36M+189% | $208.34M+182% | $107M+36.2% | ||
| $152.37M+81.6% | $169.35M+130% | $138.06M+179% | $86.83M+53.6% | $83.88M+42.2% | ||
| $2.12M+154% | $2.13M+146% | $2M+199% | $1.58M+90.0% | $834K+15.7% | ||
| $2.61M+983% | $928K+282% | $103K-59.8% | $68K-75.1% | $241K-22.5% | ||
| $610K-29.5% | $677K-26.0% | $741K-23.8% | $804K-21.9% | $865K-20.2% | ||
| $610K-29.5% | $677K-26.0% | $741K-23.8% | $804K-21.9% | $865K-20.2% | ||
| $2.61M+983% | $928K+282% | $103K-59.8% | $68K-75.1% | $241K-22.5% | ||
| $610K-29.5% | $677K-26.0% | $741K-23.8% | $804K-21.9% | $865K-20.2% | ||
| $2.61M+983% | $928K+282% | $103K-59.8% | $68K-75.1% | $241K-22.5% | ||
| $4.58M-11.4% | $5.53M-18.8% | $6.04M-16.3% | $5.98M+21.3% | $5.17M+81.9% | ||
| $4.58M-11.4% | $5.53M-18.8% | $6.04M-16.3% | $5.98M+21.3% | $5.17M+81.9% | ||
| $682K-28.7% | $753K-29.2% | $823K-30.0% | $891K-30.7% | $957K-31.4% | ||
| $128K+28.0% | $128K+36.2% | $128K+70.7% | $122K+67.1% | $100K+44.9% | ||
| —— | —— | —— | —— | —— | ||
| $2.22M+44.8% | $1.26M+34.5% | $1.38M+16.9% | $1.77M-2.1% | $1.53M-52.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Trevi Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 24.75 — current assets exceed current liabilities.
- Where does Trevi Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.